Bioengineered Regenerative Tissues
The bioactive properties
of our bioengineered tissues leverage the body’s ability to regenerate.
Our universally implantable regenerative human tissue platform contains multiple extracellular matrix (ECM) proteins that upon implantation signal the patient’s cells to repopulate and stimulate angiogenesis. The tissues repopulate with the patient’s own cells and over time, remodel into their own living tissue. Our pipeline of investigational product candidates are built on the foundational science of our Acellular Tissue Engineered Vessel (ATEV™) platform.
Example of our ATEV process
Universally Implantable1,2
During our proprietary biomanufacturing process, cells are removed from the matrix creating a universally implantable, non-immunogenic, regenerative tissue that can be evaluated for its effectiveness in treating numerous diseases, injuries, or chronic diseases.
Decellularization process1,2
Retains Key Proteins to Support Regeneration1,2
The complex biomanufacturing process thoroughly removes cells but is gentle enough to retain key ECM proteins. It is these key proteins that signal the body to support the regenerative process.1-3
are retained1-4
Post-decellularization staining1,2
Remodeling into three-layer living vessel1,2
The remodeled vessel contains a microvascularized adventitia, media layer with smooth muscle cells, and endothelial cells lining the lumen.
Infection Resistant5,6
In vitro and in vivo studies have demonstrated that the Acellular Tissue Engineered Vessel is infection resistant.
- Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc..
- Kirkton RD, et al. Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation. Sci Transl Med. 2019;11(485):eaau6934.
- Lawson JH, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet. 2016 May 14;387(10032):2026-34.
- Data on file.
- Kirkton RD, et al. Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection. J Surg Res. 2018 Jan:221:143-151.
- Wang J, et al. Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts. JVS Vasc Sci. 2023;4:100120.